PCM
KERX

Prelude Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Prelude Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,100
Closed -$167K – 2229
2015
Q1 		$167K Sell
13,100
-2,000
-13% -$25.7K 0.02% 723
2014
Q4 		$214K Buy
15,100
+5,100
+51% +$79K 0.03% 616
2014
Q3 		$138K Buy
10,000
+6,800
+213% +$104K 0.02% 904
2014
Q2 		$49K Sell
3,200
-56,900
-95% -$807K 0.01% 1367
2014
Q1 		$1.02M Buy
60,100
+57,600
+2,304% +$869K 0.14% 173
2013
Q4 		$32K Buy
+2,500
New +$29.9K 0.01% 1260

Prelude Capital Management's KERX Position: Q4 2018 in Review

Prelude Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 1,495 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in KERX in Q2 2013 and held it in 13 quarters. The position peaked at $1.65M in Q4 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Prelude Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 1,495 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $5K.
  • Prelude Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Prelude Capital Management's Keryx Biopharmaceuticals Inc position peaked at $1.65M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.